Floatz logo

Fluoroethylnormemantine

Treatment Resistant Depression

ReST TherapeuticsPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

234 Active assets in the Treatment Resistant Depression cohort.

Asset / SponsorPhaseRating
Risperdal
Johns Hopkins University
Phase 4BBB
Zelapar
Corium Innovations, Inc.
Phase 4BBB
S-Ketamine
Janssen Research & Development, LLC
Phase 4BBB
EDIVOXETINE
Eli Lilly and Company
Phase 3BBB
Opc-34712
Nova Scotia Health Authority
Phase 4BBB

View all 50 →

Same molecule, other indications

Fluoroethylnormemantine is also rated in:

neurodegenerative diseaseDormant
CC
Indicative ·
43 / 100
View asset →
post-traumatic stress disorderDormant
CC
Indicative ·
41 / 100
View asset →
brain disorderDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →